Courts may restrict access to the popular abortion medication mifepristone in the United States. Telehealth providers have backup plans in place. Abortion provider Carafem's phones were ringing nonstop over the weekend after a US federal appeals court reinstated a nationwide requirement that the drug mifepristone, one of two pills used for a medication abortion, must be obtained in person. The decision, handed down on Friday, left patients unsure if they could gain access to their treatment through telehealth. "People are afraid, and they're angry," says Carafem's chief operations officer, Melissa Grant. "I had people contact us saying, .

The United States Supreme Court has temporarily reinstated a rule allowing an abortion pill to be prescribed through telemedicine and dispensed through the mail, lifting a judicial ban that narrowed access to the medication nationwide. Justice Samuel Alito issued an interim order on Monday, pausing for one week a decision by the New Orleans-based 5th US Circuit Court of Appeals to reimpose an older federal rule requiring an in-person clinician visit to receive mifepristone. The Supreme Court's action, called an "administrative stay", gives the justices more time to review emergency requests by two manufacturers of mifepristone to ensure that the drug can be provided via telehealth and the mail while the legal challenge plays out. Alito ordered Louisiana to respond to the drugmakers' requests by Thursday and indicated that the administrative stay would expire on May 11. The court would be expected to extend the interim stay or formally decide the requests by that time.

In theory, Motif Neurotech's berry-sized device would work like a continuous glucose monitor. More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. Patients receiving the experimental new implant would not need to undergo a complicated surgery. Breakthroughs, discoveries, and DIY tips sent six days a week. Earlier this week, the United States Food and Drug Administration (FDA) approved a human trial for a blueberry-sized brain implant intended to target treatment-resistant depression.

We study semisupervised mean estimation with a small labeled sample, a large unlabeled sample, and a black-box prediction model whose output may be miscalibrated. A standard approach in this setting is augmented inverse-probability weighting (AIPW) [Robins et al., 1994], which protects against prediction-model misspecification but can be inefficient when the prediction score is poorly aligned with the outcome scale. We introduce Calibrated Prediction-Powered Inference, which post-hoc calibrates the prediction score on the labeled sample before using it for semisupervised estimation. This simple step requires no retraining and can improve the original score both as a predictor of the outcome and as a regression adjustment for semisupervised inference. We study both linear and isotonic calibration. For isotonic calibration, we establish first-order optimality guarantees: isotonic post-processing can improve predictive accuracy and estimator efficiency relative to the original score and simpler post-processing rules, while no further post-processing of the fitted isotonic score yields additional first-order gains. For linear calibration, we show first-order equivalence to PPI++. We also clarify the relationship among existing estimators, showing that the original PPI estimator is a special case of AIPW and can be inefficient when the prediction model is accurate, while PPI++ is AIPW with empirical efficiency maximization [Rubin et al., 2008]. In simulations and real-data experiments, our calibrated estimators often outperform PPI and are competitive with, or outperform, AIPW and PPI++. We provide an accompanying Python package, ppi_aipw, at https://larsvanderlaan.github.io/ppi-aipw/.

Digital Health Technologies (DHTs) including consumer wearable devices and digital health applications offer an opportunity for continuous, large-scale data collection. Wearables give insight into physiological biomarkers that help us understand the human body, through passive data collection. Such data can be collected at a regularity that would be impossible otherwise. Digital health applications provide the chance to collect diverse types of data from clinically validated surveys, GPS, and contextual inputs. This combination has the ability to make profound advances in our understanding of the factors that affect individuals on a personal and population level [Grace et al., 2025]. One of these factors is the menstrual cycle. Particularly because of its inter-individual variability, studying it requires large sample sizes, and to truly grasp its effects on the human body, it needs to be observed on a near-daily scale [Bull et al., 2019].

Deep learning underpins a wide range of applications in MRI, including reconstruction, artifact removal, and segmentation. However, progress has been driven largely by public datasets focused on brain and knee imaging, shaping how models are trained and evaluated. As a result, careful studies of the reliability of these models across diverse anatomical settings remain limited. In this work, we introduce MosaicMRI, a large and diverse collection of fully sampled raw musculoskeletal (MSK) MR measurements designed for training and evaluating machine-learning-based methods. MosaicMRI is the largest open-source raw MSK MRI dataset to date, comprising 2,671 volumes and 80,156 slices. The dataset offers substantial diversity in volume orientation (e.g., axial, sagittal), imaging contrasts (e.g., PD, T1, T2), anatomies (e.g., spine, knee, hip, ankle, and others), and numbers of acquisition coils. Using VarNet as a baseline for accelerated reconstruction task, we perform a comprehensive set of experiments to study scaling behavior with respect to both model capacity and dataset size. Interestingly, models trained on the combined anatomies significantly outperform anatomy-specific models in low-sample regimes, highlighting the benefits of anatomical diversity and the presence of exploitable cross-anatomical correlations. We further evaluate robustness and cross-anatomy generalization by training models on one anatomy (e.g., spine) and testing them on another (e.g., knee). Notably, we identify groups of body parts (e.g., foot and elbow) that generalize well with each other, and highlight that performance under domain shifts depends on both training set size, anatomy, and protocol-specific factors.

Accurately identifying patients with specific medical conditions is a key challenge when using clinical data from electronic health records. Our objective was to comprehensively assess when weakly-supervised prediction methods, which use silver-standard labels (proxy measures of the true outcome) rather than gold-standard true labels, perform well in rare-outcome settings like vaccine safety studies. We compared three methods (PheNorm, MAP, and sureLDA) that combine structured features and features derived from clinical text using natural language processing, through an extensive simulation study with data-generating mechanisms ranging from simple to complex, varying outcome rates, and varying degrees of informative silver labels. We also considered using predicted probabilities to design a chart review validation study. No single method dominated the other across all prediction performance metrics. Probability-guided sampling selected a cohort enriched for patients with more mentions of important concepts in chart notes. SureLDA, the most complex of the three algorithms we considered, often performed well in simulations. Performance depended greatly on selected tuning parameters. Care should be taken when using weakly-supervised prediction methods in rare-outcome settings, particularly if the probabilities will be used in downstream analysis, but these methods can work well when silver labels are strong predictors of true outcomes.

Multimodal representation learning is commonly built on a shared-private decomposition, treating latent information as either common to all modalities or specific to one. This binary view is often inadequate: many factors are shared by only subsets of modalities, and ignoring such partial sharing can over-align unrelated signals and obscure complementary information. We propose Hierarchical Contrastive Learning (HCL), a framework that learns globally shared, partially shared, and modality-specific representations within a unified model. HCL combines a hierarchical latent-variable formulation with structural sparsity and a structure-aware contrastive objective that aligns only modalities that genuinely share a latent factor. Under uncorrelated latent variables, we prove identifiability of the hierarchical decomposition, establish recovery guarantees for the loading matrices, and derive parameter estimation and excess-risk bounds for downstream prediction. Simulations show accurate recovery of hierarchical structure and effective selection of task-relevant components. On multimodal electronic health records, HCL yields more informative representations and consistently improves predictive performance.

Fréchet regression, or conditional Barycenters, is a flexible framework for modeling relationships between covariates (usually Euclidean) and response variables on general metric spaces, e.g., probability distributions or positive definite matrices. However, in contrast to classical barycenter problems, computing conditional counterparts in many non-Euclidean spaces remains an open challenge, as they yield non-convex optimization problems with an affine structure. In this work, we study the existence and computation of conditional barycenters, specifically in the space of positive-definite matrices with the Bures-Wasserstein metric. We provide a sufficient condition for the existence of a minimizer of the conditional barycenter problem that characterizes the regression range of extrapolation. Moreover, we further characterize the optimization landscape, proving that under this condition, the objective is free of local maxima. Additionally, we develop a projection-free and provably correct algorithm for the approximate computation of first-order stationary points. Finally, we provide a stochastic reformulation that enables the use of off-the-shelf stochastic Riemannian optimization methods for large-scale setups. Numerical experiments validate the performance of the proposed methods on regression problems of real-world biological networks and on large-scale synthetic Diffusion Tensor Imaging problems.

Understanding how biomarker distributions evolve over time is a central challenge in digital health and chronic disease monitoring. In diabetes, changes in the distribution of glucose measurements can reveal patterns of disease progression and treatment response that conventional summary measures miss. Motivated by a 26-week clinical trial comparing the closed-loop insulin delivery system t:slim X2 with standard therapy in children with type 1 diabetes, we propose a probabilistic framework to model the continuous-time evolution of time-indexed distributions using continuous glucose monitoring data (CGM) collected every five minutes. We represent the glucose distribution as a Gaussian mixture, with time-varying mixture weights governed by a neural ODE. We estimate the model parameter using a distribution-matching criterion based on the maximum mean discrepancy. The resulting framework is interpretable, computationally efficient, and sensitive to subtle temporal distributional changes. Applied to CGM trial data, the method detects treatment-related improvements in glucose dynamics that are difficult to capture with traditional analytical approaches.